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Purpose: To explore in a prospective trial the prognostic value of hypoxia imaging before and during
radiochemotherapy in patients with locally advanced head and neck cancer.
Patients and methods: Twenty-ﬁve patients with stage III/IV head and neck cancer were investigated with
[18F]-ﬂuoromisonidazole (FMISO) PET/CT at four time points during radiochemotherapy (baseline, 8–
10 Gy, 18–20 Gy,50–60 Gy). FMISO PET/CT image parameters were extracted including maximum-
tumour-to-background (TBRmax) and thresholded volume at different TBR ratios. CT volume and baseline
FDG-PET/CT image parameters were also included. Parameters at all time points were investigated for
their prognostic value with the local-progression-free-survival endpoint (LPFS). Signiﬁcance was evalu-
ated with multivariate Cox (including clinical parameters) and Log-rank tests.
Results: FMISO-image parameters were found to have a strong association with the LPFS endpoint, and
were strongest at the week 1 and 2 time points (p = 0.023–0.048 and 0.042–0.061 respectively on mul-
tivariate Cox). Parameters measured at baseline were only signiﬁcant on univariate analysis. None of
the clinical parameters, and also FDG- or CT-delineated volumes, were signiﬁcantly associated with LPFS.
Conclusion: This prospective, exploratory study demonstrated that FMISO-PET/CT imaging during the ini-
tial phase of treatment carries strong prognostic value. FMISO-PET/CT imaging at 1 or 2 weeks during
treatment could be promising way to select patients that would beneﬁt from hypoxia modiﬁcation or
dose-escalated treatment. A validation study is on-going.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 105 (2012) 21–28Hypoxia is characteristic of solid tumours, inﬂuences malig-
nancy and contributes to treatment failure (Chapters 15 and 16,
[36]). A recent meta-analysis from randomised trials demonstrated
that hypoxia modiﬁcation, such as use of carbogen inhalation and
nimorazole [17], or nimorazole alone [26], improves local tumour
control, disease-speciﬁc and overall survival [24]. Grouping pa-
tients according to hypoxic status, in the ARCON, TASMAN 92.02
and DAHANCA 5 studies, showed that patients with hypoxic tu-
mours yield a much greater beneﬁt from these treatments
[16,29,35]. Furthermore, in a handful of imaging studies, hypoxia
PET/CT imaging, as a non-invasive alternative to electrode mea-
surements, has been shown to provide prognostic information
[7,8,11,18,21,27,28]. Thus, while these imaging studies were small,
hypoxia-tracer-PET/CT appears to be a promising method for
assessing hypoxia-related tumour resistance, and, furthermore,adiotherapy Group, OncoRay,
arus, Technische Universität
y.
rin).
er CC BY-NC-ND license.may be of use to select patients that may beneﬁt from hypoxia
modiﬁcation or intensiﬁed radiation therapy treatments.
The extent of tumour hypoxia and the capacity for reoxygena-
tion during radiotherapy vary amongst patients. If tumours
partially or fully reoxygenate during treatment, then a single pre-
treatment measurement of hypoxia is unlikely to be a meaningful
parameter for patient stratiﬁcation. Nevertheless, pre-treatment
PET/CT signal from hypoxia PET-tracers has been found in several
studies to be prognostic for response to radiotherapy in the head
and neck [8,11,18,21,27,29,34]. A study from Leuven in 15 patients
performed [18F]-ﬂuoromisonidazole positron emission tomogra-
phy (FMISO PET/CT) imaging at baseline and during radiotherapy
[9], ﬁnding both maximum tumour-to-blood ratio (T/B) at baseline
and after 30 Gy prognostic for disease-free survival. A similar study
in 14 patients from Tübingen found no prognostic signiﬁcance of
FMISO PET/CT during treatment, but was able to show that the hy-
poxia decreased in most patients during treatment [10].
Our hypothesis is that the individual dynamics of reoxygenation
during radiotherapy in each head and neck cancer will play a role
in the overall tumour response, with tumours that reoxygenate
early during therapy having a more favourable prognosis. It is then
Table 1
Patient and treatment characteristics (n = 25).
Characteristic Value
Age (mean, range) 59 years (45–
76)
Gender (female/male) 3/22
Primary site
Oral cavity/oropharynx/hypopharynx/larynx 6/9/7/3
T-stage (T3/T4) 9/16
N-stage (N0/N1/N2a/N2b/N2c/N3) 5/2/0/3/12/2
Stage (III/IV) 3/22
GTVprimary* (median, range) 45 cm3 (7–308)
p16 status (positive/negative/not available) 7/14/4
Radiation dose (mean, range) 72 Gy (69–72)
Overall treatment time (mean, range) 41 days (39–
46)
Chemotherapy
Cisplatin/5-Fu (patients, mean number of cycles, range) 21/6 (3–6)
Mitomycin C/5-Fu (patients, mean number of cycles,
range)
4/2 (2–2)
* Deﬁned by CT.
22 FMISO-PET in outcome prediction of HNSCCimportant to establish the optimal time point for performing hy-
poxia PET/CT imaging to stratify patients for more aggressive treat-
ments. Here we report results from a hypothesis-generating study
of sequential FMISO PET/CT imaging in head and neck cancer pa-
tients undergoing radiochemotherapy. The general approach of
our prospective imaging trial, accruing 50 patients, is to collect
imaging data into an exploratory and a validation cohort, with 25
patients per cohort. While trial is still on-going, we report here
the results from our exploratory cohort, where four imaging time
points are tested for their prognostic value. We also investigate
which FMISO PET/CT image parameter is strongest for assessment
of hypoxia with PET/CT, e.g. hypoxic volume – measured from a gi-
ven tumour-to-background ratio (TBR) threshold, or maximum sig-
nal intensity.Patients and methods
Patients
The imaging trial, recruiting up to 50 patients, was split into an
exploratory and a validation cohort. A total of 28 patients were re-
cruited between July 2006 and July 2009. Three patients withdrew
from their imaging appointments during treatment, leaving a total
of 25 patients that are included in this exploratory cohort analysis.
The characteristics of the remaining 25 patients are summarised in
Table 1. The study (NCT00180180) was approved by the German
Federal Radiation Protection Authority (Bundesamt für Strahlens-
chutz) and the local Ethics Committee. Accrual of a second cohort
with 25 planned patients is currently on-going. Inclusion criteria
included written informed consent, age older than 18 years, histo-
logically-proven squamous cell carcinoma of the head and neck
that was not operated (for various oncological and non-oncological
reasons), WHO performance status 0–2 and tumour location and
extent suitable for radiotherapy with curative intent. The exclusion
criteria were presence of distant metastases, previous radiotherapy
in the head and neck region, previous history of malignant disease
(other than T1 skin cancer or CIS of the uterine cervix), pregnancy
and lacking capacity to consent.Work-up, treatment and follow-up
The staging procedures included clinical examination, endos-
copy, ultrasound, contrast-enhanced CT or MRI and FDG PET/CT
scans. For imaging and treatment the patients’ head and shoulders
were immobilised in the supine position using a thermoplasticmask. Using all available information on disease localisation and
extent, the gross tumour volume (GTV) and subsequently clinical
target volume as well as planning target volume were deﬁned in
the CT-component of the baseline FDG-PET/CT. Treatment plan-
ning with 3D-conformal or intensity-modulated radiotherapy (He-
lax TMS 6.1A.1, since September 2008 Oncentra Masterplan 3.1,
Nucleotron) aimed for uniform coverage of the PTV (95–107% of
the prescribed dose), while aiming to maintain dose to the spinal
cord (Dmaz < 45 Gy) and sparing the larynx (Dmean < 45 Gy) and par-
otid glands (Dmean < 26 Gy). Doses of 72 Gy in 6 weeks were pre-
scribed to the primary tumour and involved lymph nodes (PTV1)
and of 59.4 Gy in 5 weeks to the lymphatic regions at risk for
microscopic disease (PTV2). The ﬁrst 30 Gy were given with con-
ventional fractionation followed by 1.4 Gy twice daily for the
remainder of the treatment. This followed a hyperfractionated,
accelerated fractionation regimen that has been validated in a ran-
domised trial, and is frequently used in Germany [5]. In one patient
conventional fractionation with 70 Gy in 7 weeks (PTV1) and 50 Gy
in 5 weeks (PTV2) was given. Concurrent chemotherapy consisted
of 5-ﬂuorouracil (continuous infusion, 120 h, 600 mg/m2/day on
days 1–5) and weekly cisplatin (30 mg/m2) or mitomycin C
(10 mg/m2, days 5 and 36)[13]. Patients were followed-up 4 weeks
after the end of treatment, then every 3 months for 2 years and at a
6-month frequency thereafter. Follow-up visits included clinical
examination and alternating FDG-PET/CT or MRI.PET/CT imaging
PET data acquisition was done using a Biograph 16 W PET/CT
(Siemens Medical Solutions Inc., Knoxville, TN, USA) containing a
16-slice CT scanner. The FMISO-PET tracer was delivered from
the Institute of Radiopharmacy at the Helmholtz Centre in Dres-
den-Rossendorf, and was synthesised as previously pub-
lished[33].The imaging schedule included four time points as
follows: before RCT, after a mean dose of 8–10 Gy (end of week
1), of 18–20 Gy (end of week 2) and of 50–60 Gy (during week 5)
during RCT. Most patients (19/25) attended all four imaging time
points. However, due to logistic reasons in six patients imaging
at 10 Gy or 20 Gy was not possible. Similarly, it was not possible
to image at the same day during the course of RCT in every patient.
The pre-therapeutic FMISO-PET imaging was acquired 2–4 days
after FDG-PET/CT imaging.
Static FMISO images were acquired at both 2 h and 4 h post
injection (p.i.) after administration of 250–300 MBq. For each data-
set one ﬁeld of view (FOV; 16 cm in z-axis) was scanned for 15 min
as a three-dimensional emission scan. The acquisition time, for the
emission only, was 12 min. Emission images with CT-based atten-
uation-correction were reconstructed using four iterations, eight
subsets and a 1 mm 3D Gaussian ﬁlter.
Before RCT an initial diagnostic whole body FDG-PET/CT, 60 min
p.i. of 350 MBq [18F]-FDG (GlucoRos, Helmholtz Centre Dresden-
Rossendorf, Germany), was acquired in every patient for staging.
CT scans for attenuation correction, as well as for electron density
determination, were performed in cranio-caudal direction from
skull base to upper thighs. Scanning parameters included
100 mAs, 120 kV, online tube current modulation, 1.5 mm slice
collimation, 0.5–0.75 s rotation time, and reconstruction of 5 mm
slices. For diagnostic purposes and radiotherapy planning, con-
trast-enhanced CT scans were performed in most patients, using
120 ml of iodinated contrast material (Ultravist 370, Bayer Scher-
ing Pharma, Leverkusen, Germany). The acquisition time per bed
position for the emission FDG-PET scan was 3 min. Uncorrected
emission images and CT-based attenuation-corrected images were
reconstructed, both using four iterations, eight subsets and a 5 mm
3D Gaussian ﬁlter.
Fig. 1. Diagram of treatment and imaging workﬂow for the study.
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tioned as for treatment. This ensured reproducible positioning,
not only during radiation, but also during consecutive FMISO-
and FDG-PET/CT.Image analysis and data evaluation
PET/CT scans from different time points before and during treat-
ment were imported into ROVER image analysis program (ABX,
Radeberg, Germany). The scan set included the FDG- and the FMI-
SO-PET/CT images taken before treatment commencement and the
three FMISO-PET/CT images taken during treatment (see Fig. 1 for
imaging schedule). The FMISO images selected for the analysis
were those obtained 4 h p.i., since it was found in an earlier study
from our institution that the 4 h images have superior contrast [1].
Each image in this scan set was co-registered to the pre-thera-
peutic CT (from the baseline FDG-PET/CT scan) using the CT-com-
ponent of the FMISO-PET/CT scans using a rigid-registration
algorithm (mutual information). This was possible since the pa-
tient had been set-up in each PET/CT scan in the same position
using the radiotherapy mask. Weight loss in some patients caused
the registration to be less straight-forward. In these cases, the reg-
istration was performed manually by viewing the anatomy in the
vicinity of the tumour, and prioritising this region for matching.
All registered scan sets were checked for matching precision by
an experienced radiologist (NA). In a ﬁrst step, an ellipsoidal region
was drawn around the metabolically active tumour on the coregis-
tered FDG-PET scan by visual inspection based on the apparent
voxel signal. It included the primary tumour while excluding in-
volved lymph nodes. This volume-of-interest (VOI) was used sub-
sequently to mask the coregistered FMISO PET images. This was
important so that measurement of the FMISO avid region did not
include involved lymph nodes and regions of uptake in normal
tissue.
A tumour-to-background-based thresholding technique was
used to generate VOIs encompassing the regions of increased activ-
ity concentration on the FMISO-PET scans, or the hypoxic volume
(HV). This was done step-wise as follows. The background mea-
surement was obtained by generating ellipsoidal VOIs of approxi-
mately 20 cm3 (or 200 PET voxels) in the deep-neck muscle in
each FMISO scan. The CT-component of the PET/CT scans was used
to guide delineation of the neck muscle excluding bone and larger
amounts of fat. The mean voxel value within this neck muscle VOI
was used for the background measurement (B). HV was volume-
thresholded at a range of tumour-to-background threshold levels
(TBR) after a given dose (D), HVTBR,D and location of this centre ofthe HV was measured. Four TBR threshold levels ([1.4, 1.6, 1.8,
2.0]  B) were applied so that the most appropriate threshold level
could be evaluated. Other potentially relevant parameters were
also obtained. These included the baseline fractional hypoxic vol-
ume (as a fraction of CT-delineated tumour volume at baseline,
HFTBR), maximum TBR and maximum SUV in the volume after dose,
D, (TBRmax, D, SUVmax, D), the metabolic tumour volume (MTV) seg-
mented on FDG-PET/CT, and maximum SUV from the baseline
FDG-PET (SUVmax, fdg). The segmentation algorithm used for the
MTV was a background-subtraction adaptive-thresholding tech-
nique available within the ROVER software [14].The maximum
TBR and SUV were determined by ﬁnding the mean value within
the highest-valued voxels representing 0.5 cm3 of tissue (this coin-
cided approximately with the mean of the values above the 95th
percentile).
To test the strength of each imaging parameter univariate and
tentative (due to the low patient number) multivariate analyses
were performed using the Cox proportional hazards model. Mul-
ti-variate analysis was performed to test the strength of each im-
age parameters against clinical parameters T, N and HPV status.
Log-rank tests were also performed stratifying the patients by
the median of the image parameter. Kaplan–Meier curves were
plotted for patient groups by the median TBRmax for all imaging
time points.Results
Median follow-up of all patients was 12 months (range 2–58).
At time of analysis nine patients are alive with a median follow-
up of 32 months (range 20–58). Five patients died from intercur-
rent disease without evidence of disease progression within the
ﬁrst 6 months during follow-up. Local failures were observed in
eight patients resulting in a local recurrence free survival at 3 years
of 57%. Among them one patient showed in addition a nodal fail-
ure. In one patient a distant metastasis was detected at 5 months
following treatment, and then, 7 months later, a local failure was
detected.
Twenty-one patients out of 25 (84%) had a hypoxic volume at
baseline (HV1.6, 0Gy > 1 cm3 or 13 PET voxels). Median fractional
hypoxic volume (HF) at baseline, using TBR = 1.4, 1.6, 1.8 and 2.0
for thresholding, was 0.66, 0.26, 0.15 and 0.04 respectively. Median
hypoxic volume (thresholded at all TBRs) and median TBRmax de-
creased as treatment progressed (see Table 2). A hypoxic subvo-
lume (HV1.6, 57Gy > 1cm3) remained in 10/24 patients in week 5 of
treatment. The FDG volume of the primary tumour at baseline
Table 2
Hypoxia imaging parameters before and during radiochemotherapy. Data represent median and range. Hypoxic volumes (HV) were calculated using 1.4, 1.6, 1.8 and 2.0 as
threshold relative to the background. TBRmax represents the maximum ratio between FMISO up-take in the tumour and the background, i.e. in the deep neck muscles.
Parameter Baseline (0 Gy) Week 1 (8–10 Gy) Week 2 (18–20 Gy) Week 5 (51–57 Gy)
HV1.4 (cm3) 31.5 (0.4–155.1) 28.2 (0–143.1) 21.8 (0–115.6) 2.0 (0–48.4)
HV1.6 (cm3) 13.2 (0–101.0) 11.6 (0–99.2) 6.0 (0–69.5) 0.3 (0–10.2)
HV1.8 (cm3) 5.8 (0–70.8) 3.1 (0–63.1) 0.4 (0–38.3) 0 (0–5.69)
HV2.0 (cm3) 2.0 (0–59.8) 1.0 (0–34.1) 0.1 (0–28.2) 0 (0–1.1)
TBRmax 2.2 (1.4–4.0) 2.2(2.0–3.9) 1.9 (1.7–3.4) 1.7 (1.5–2.2)
SUVmax 2.6 (1.9–4.3) 2.5 (1.7–4.3) 2.2 (1.0–3.8) 1.7 (0.3–2.4)
Fig. 2. Plots showing reoxygenation behaviour of tumours that (a) recurred and (b) were controlled. HV_1.6 denotes hypoxic volume generated from thresholding at a level of
1.6 times background. Relative HV_1.6 was relative to the baseline volume thresholded for each patient.
24 FMISO-PET in outcome prediction of HNSCC(thresholded at 40% of maximum) ranged between 4 and 136 cm3,
and correlated strongly with the volume manually-delineated on
the contrast-enhanced CT (R2 = 0.88). CT volume correlated signif-
icantly with baseline hypoxic volumes HV1.4, 0Gy and HV1.6, 0Gy, but
not with HV1.8, 0Gy and HV2.0, 0Gy (Pearson’s correlation coefﬁcients
of 0.585, 0.383, 0.321, 0.265 respectively).
A range of behaviours in tumour reoxygenation were found. To
demonstrate this the HV1.6 relative to baseline for each patient
over the four imaging time points are plotted in Fig. 2, both for
responders and non-responders. There were tumours that showedonly a very small hypoxic subvolume at baseline, and then exhib-
ited large hypoxic volumes at the 10 and 20 Gy time points. Tu-
mours with hypoxic volumes that did not resolve at 20 Gy (to
below the baseline-measured volume) 3/3 recurred. Others had a
progressive decrease in hypoxic volume after the start of treatment
or after the 10 Gy time point.
On Cox analysis, none of the clinical parameters were signiﬁ-
cantly associated with local recurrence. Neither the FDG- or CT-
delineated volumes nor HPV status was signiﬁcantly associated
with local recurrence on uni- or multivariate analysis (p = 0.34,
D. Zips et al. / Radiotherapy and Oncology 105 (2012) 21–28 251.0 and 0.24 respectively). The hypoxic volume (using all thresh-
olds) and TBRmax were most signiﬁcantly associated with local
recurrence at the 8–10 Gy and 18–20 Gy time points on both
uni- and multi-variate Cox analyses (see Table 3). Image parame-
ters measured at the baseline and the week 5 imaging time points
were only signiﬁcant on univariate Cox analysis. The Hazard Ratio
(HR) of the hypoxic volume on univariate Cox analysis increased
signiﬁcantly with the threshold level used at 18–20 Gy (1.03–
1.14), while the TBRmax, 20Gy carried a HR of 4.25. Comparing the
p-values and the HRs of SUVmax and TBRmax on multivariate Cox
analysis, TBRmax appeared to be a stronger parameter at baseline
or 18–20 Gy. However, at 8–10 Gy they had comparable strength.
Log-rank tests, for groups above and below the median of each
of the image parameters, revealed signiﬁcant difference between
the groups for TBRmax, 20Gy, TBRmax, 57Gy, HV1.6, 10Gy, HV1.6, 20Gy,
HV1.8, 20Gy, HV2.0, 20Gy, HV1.8, 57Gy, HV2.0, 57Gy. The median values
of all parameters at all-time points are given in Table 2. It can be
seen that a TBRmax of around 2.0 was a strong cut-off point be-
tween high and low risk groups at the ﬁrst three imaging time
points (Fig. 3).Discussion
In this prospective exploratory study we show that measure-
ment of hypoxia with FMISO PET/CT is a promising biomarker to
distinguish patients at increased risk from local recurrence. The
study design included three imaging time points during radioche-
motherapy, enabling the time course of reoxygenation to be
studied.Table 3
Univariate and multivariate Cox model p-value for image parameters is also given for test
Time point Parameter HR univariate
Baseline Age 0.98
T stage 0.79
N stage 4.39
p16 status 0.59
GTVprimary (CT) 1.00
FDG SUVmax 0.97
FDG Vol 1.01
HV1.4 1.03
HV1.6 1.04
HV1.8 1.05
HV2.0 1.06
HF1.4 1.53
HF1.6 3.52
HF1.8 17.66
HF2.0 176.7
FMISO TBRmax 5.16
FMISO SUVmax 2.35
Week 1 (8–10 Gy) HV1.4 1.02
HV1.6 1.02
HV1.8 1.03
HV2.0 1.06
FMISO TBRmax 2.76
FMISO SUVmax 2.72
Week 2 (18–20 Gy) HV1.4 1.02
HV1.6 1.03
HV1.8 1.07
HV2.0 1.14
FMISO TBRmax 4.25
FMISO SUVmax 3.85
Week 5 (51–57 Gy) HV1.4 1.03
HV1.6 1.14
HV1.8 1.18
HV2.0 16.8
FMISO TBRmax 20.1
FMISO SUVmax 1.57A particularly intriguing result of our study was that at early
imaging time points during treatment, image characteristics be-
came stronger prognostic parameters (compared to baseline), and
were signiﬁcant on multivariate analysis, albeit with limited power
due to the low number of patients. This result is in line with pre-
clinical experiments at our centre, where it was found that tumour
control probability in human head and neck cancer xenografts cor-
related with hypoxic fraction after 10 fractions of 2 Gy, but only
weakly [38] or not at baseline [39].
Our ﬁndings at baseline on univariate analysis agreed with
other studies where hypoxic-tracer-PET imaging at baseline was
reported to have prognostic value [9,11,18,21,27,29]. However,
our results showed that the baseline image parameters were not
the strongest predictors of local recurrence, as evidenced by their
lack of signiﬁcance on multivariate analysis and in part in the
log-rank tests. There are little data from hypoxia imaging during
treatment. Dirix et al. [8] found that maximum tumour-to-blood
ratio >1.17 during treatment correlated with disease-free survival
in a smaller cohort of 15 patients, with seven recurrences. However
this maximum tumour-to-blood cannot be directly compared to
our values, since the earlier study used blood samples to measure
the background activity concentration. A report of FMISO-PET/CT
imaging from Lee et al. [20] found that only 2/16 oropharyngeal
carcinoma patients had hypoxia at week 4 of therapy, and pre-
or during treatment FMISO PET/CT imaging parameters had no
prognostic value. Eschmann et al. [10] also performed FMISO
PET/CT imaging during treatment. But this study did not attempt
to draw correlations with treatment outcome due to the small
sample size (n = 14). This highlights the fact that small study sam-
ples can result in varying results, which must in part be due to theing with nodal and HPV status. HR denotes Hazard Ratio obtained.
p-Value HR multivariate p-Value
0.657 1.06 0.417
0.753 0.48 0.337
0.167 3.66 0.163
0.529 0.43 0.239
0.468 1.00 0.579
0.651 0.97 0.750
0.208 1.01 0.335
0.053 1.05 0.212
0.018 1.07 0.117
0.028 1.08 0.154
0.025 1.13 0.151
0.402 1.60 0.424
0.346 11.46 0.193
0.090 16.13 0.162
0.032 179.8 0.148
0.022 12.85 0.139
0.139 1.77 0.444
0.047 1.02 0.068
0.047 1.04 0.033
0.040 1.07 0.023
0.024 1.12 0.020
0.025 6.04 0.040
0.024 3.79 0.060
0.035 1.05 0.042
0.021 1.08 0.045
0.011 1.12 0.042
0.013 1.62 0.047
0.008 6.19 0.061
0.015 3.72 0.169
0.212 1.04 0.237
0.183 1.33 0.129
0.029 6541 0.132
0.027 10,194 0.106
0.048 10,088 0.059
0.559 2.18 0.453
Fig. 3. Local-progression-free survival of patients stratiﬁed by the median value of the maximum tumour-to-background (TBRmax) at the given imaging time point.
26 FMISO-PET in outcome prediction of HNSCClarge variation in radiation response that is known to exist in tu-
mours [37]. Nevertheless, Horsman et al. recently published a
meta-analysis that concurs with our study results, showing that
hypoxia imaging with PET/CT has predictive value [15].
Different reoxygenation proﬁles of tumours may partly explain
why hypoxia measurement during treatment was most optimal for
prediction of local recurrence in our study. A range of behaviours in
tumour reoxygenation was found, which was in line with the pre-
clinical studies mentioned above and data published previously by
our group [4] and previous accounts where hypoxia was measured
in patients with Eppendorf electrodes [6,32]. An interesting ﬁnding
was that some tumours having a small hypoxic subvolume at base-
line then increased in size at the 10 Gy time point. Stadler et al.
[32] also observed this behaviour in a small group of head and neck
tumours. Apart from temporary impairment of perfusion with sub-
sequent increase in hypoxia early during radiotherapy one may
speculate about a different explanation. In FMISO PET/CT imaging
the delivery of the tracer to the site of hypoxia is critical. In poorly
perfused regions of tissue, which are by this very fact subject to hy-
poxia, tracer delivery and wash-out will be hampered, and thus the
fraction of bound FMISO in a region may not reﬂect the underlying
level of hypoxia. After several radiotherapy fractions it is conceiv-
able that perfusion improves, leading to better tracer delivery and
wash-out of unbound tracer. However, despite partial reperfusion
of some regions, allowing for faster delivery and wash-out of the
tracer, hypoxia may still remain in regions that are at a distance
from the perfused vessels. In this case, this remaining hypoxia will
be imaged with a higher ﬁdelity. Modelling studies have indeed
demonstrated that due to the tracer dynamics and vascular frac-
tion a confounding picture on imaging may result [22]. To further
explore this potential mechanism, perfusion measurements from
dynamic-contrast-enhanced MRI [23] or CT [2] may be able to
add complementary information to hypoxia imaging, and help togive a clearer picture of tumour microenvironment. Additionally,
a less lipophilic tracer compound, such as [18F]-FAZA, may improve
tracer distribution in the tumour by facilitating faster wash-out of
non-bound tracer [12,31].
The message coming out of hypoxia modiﬁcation trials in head
and neck is that patients should be selected for hypoxia modiﬁca-
tion based on hypoxia status of the tumour cancer (DAHANCA 5
[25], TASMAN 92.02 [29], ARCON [16]). The same should hold true
for radiation dose-escalation strategies. Thus, deriving a reliable
predictive biomarker from FMISO PET/CT imaging is extremely rel-
evant. A convenient ﬁnding of the present study was the ability to
select the high risk patients at early time points during treatment.
This would be an advantage selection of patients for more aggres-
sive treatment regimes, either hypoxic modiﬁcation or radiation
dose escalation. On the other hand, it may be advantageous to per-
form FMISO PET/CT later in treatment for the purposes of adaptive
radiotherapy. Studies have shown signiﬁcant tumour shrinkage in
the head and neck during treatment, indicating some beneﬁt from
adapting radiotherapy treatment volumes [3,30]. This strategy
could potentially maximise the boost dose prescription to high risk
tumours while keeping within normal tissue tolerances.
Since the patient data from this study will be evaluated in two
halves – an exploratory and a validation cohort – patient numbers
in the present study were limited. Furthermore, missed imaging
appointments in six patients (three patients at 10 Gy and three
at 20 Gy) limited the statistical power. We propose this as a reason
for which the N stage and HPV status were not found to be signif-
icantly associated with local recurrence, in disagreement with pre-
vious studies. There were also contradictory results found between
Cox and log-rank tests at the baseline time point, where hypoxia
imaging parameters were not signiﬁcant on log-rank while being
signiﬁcant on univariate Cox analysis (see Fig. 3 for the K-M plot
and Table 3). This could partially be explained by the fact that
D. Zips et al. / Radiotherapy and Oncology 105 (2012) 21–28 27the Cox model uses the parametric data, i.e. the magnitude of the
imaging parameter of interest, while the log-rank tests groups
above and below the median. Nevertheless, since the cohort was
small, all statistical testing, especially multivariate analysis will
be sensitive to outliers, and should be interpreted with caution.
This will be addressed in the validation cohort and overall analysis
of the whole data set and in a planned multi-institutional meta-
analysis of individual patient data within the German Consortium
for Translational Cancer Research (DKTK).
In order to ﬁnd the hypoxic volume we used tumour-to-back-
ground-based segmentation techniques. While all due care was ta-
ken to ensure this method was consistent throughout the patient
group, it was observed this method is sensitive to placement of
the background ROI and signal noise within the background. In
the study, the standard deviation of voxel values in the background
ROI of 200 voxels was around 10%. This could lead to large uncer-
tainties in volume thresholding, especially for lower contrasts
encountered at the later treatment time points. However, the use
of a large ROI was justiﬁed due to the large component of statistical
noise inherent in low activity concentration regions, such as the
background. The ROI size led to a lower standard error on the mea-
surement given a high number of sampled voxels. Furthermore,
segmentation of PET data based on voxel intensities, especially at
low contrast-to-noise ratios, contains further sources of error, as
carefully described by a recent publication [19]. The partial volume
effect is known to confound quantitative information from PET
images. For small tracer-avid volumes (<2 cm in diameter), the
hypoxic volume will be underestimated due to poor recovery of
the actual activity concentration in the voxels. Secondly, for phys-
iological tracer accumulation, especially in hypoxia imaging where
the ground truth is a pattern of ribbon-like accumulations on the
micron scale, the image does not reﬂect the form of the hypoxic
subvolumes. The signal arising from a voxel is rather a volume-
average of hypoxic regions distributed within a voxel-sized volume
of tissue. Thus, we acknowledge that hypoxic volume on threshold-
ing can only be regarded as semi-quantitative. Currently, from the
data available and the consideration given above, we would not
propose that segmentation of FMISO-PET using thresholding could
render the precise ‘‘high risk’’ subvolumes for dose-painted radia-
tion therapy, especially at the currently available spatial resolution
and contrast-to-noise ratio.
In conclusion, the present study explored the use of FMISO PET/
CT before and during treatment as a way to select patients at high
risk of developing local recurrence. We showed that FMISO imag-
ing during the initial phase of treatment carries strong prognostic
value for identifying patients at risk from local recurrence. On the
other hand, baseline imaging was not found to be as strong in com-
parison, as different treatment-related reoxygenation proﬁles exist
within individual tumours.
Overall, our exploratory study suggests that FMISO PET/CT
imaging at 1 or 2 weeks during treatment is a promising way to se-
lect patients that may beneﬁt from hypoxia modiﬁcation or dose-
escalated treatment. This ﬁnding needs further evaluation and val-
idation in an independent data set, which is underway.Conﬂict of interest statement
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